Soy protein isolate (SPI) is known to reduce the risk of heart disease by lowering serum cholesterol and triacylglycerol (TG) levels. Soybean -conglycinin, which is a component of SPI, might be the active ingredient that prevents and/or ameliorates lifestyle-related diseases, such as hyperlipidemia and obesity. This study aimed to determine the efficacy of soybean -conglycinin for lowering the human serum TG level and visceral fat. Randomized double-blind placebo-controlled designs were used to test the effect of dietary -conglycinin, which was taken in the form of candy. 
Introduction
Hypercholesterolemia has been recognized to be a major risk factor for cardiovascular disease. However, recently, multiple risk factor clustering syndrome, or metabolic syndrome, has been noted as a highly atherogenic state independent of hypercholesterolemia.
In this syndrome, a variety of disorders, includ-ing hypertriglyceridemia cluster in one individual and visceral fat accumulation, is shown to act as a key player.
The US Food and Drug Administration (FDA) has approved for food labeling the health claim that the consumption of 25 g of soy protein isolate (SPI) per day reduces the risk of heart disease 1) . This reduction of heart disease risk results from decreases in the serum cholesterol and triacylglycerol (TG) levels mediated by SPI 2) . Many studies on the hypocholesterolemic effects of SPI support the hypothesis that polypeptides with high bile acid-binding capacity could inhibit the reabsorption of bile acid in the ileum, or decrease the micellar solubility of cholesterol in small intestinal epithelial cells and decrease the serum cholesterol level [3] [4] [5] [6] . SPI is mainly composed of two major storage proteins, glycinin and -conglycinin. Previously, it was reported by this laboratory that -conglycinin decreased plasma TG concentrations in young and adult rats 7) , and that -conglycinin reduced TG levels in patients with hyperlipidemia who consumed -conglycinin for 4 weeks in a small-scale clinical trial 8) . Moreover, -conglycinin consumption was shown to reduce or suppress increases in the body fat ratio in healthy female volunteers with a high baseline body fat ratio by the bioelectrical impedance method 9, 10) . These reports suggested that -conglycinin may be a food ingredient that could be used to prevent and/ or ameliorate lifestyle-related diseases, such as hyperlipidemia and obesity. A mechanism for the hypolipidemic activity of soybean -conglycinin was reported. It was found that soybean -conglycinin lowered the activity of fatty-acid synthase and increased the activities of -oxidation enzymes, and that fecal excretion of TG was high in -conglycinin-fed mice and rats 11, 12) . This study was performed to evaluate the efficacy of soybean -conglycinin in lowering the human serum TG level, as well as the reduction of visceral fat observed with computed tomography (CT) scan around the umbilicus 13) , in a randomized controlled trial (RCT).
Materials

Experimental Food
Soybean -conglycinin was manufactured by the method developed previously 14) , and administered in the form of candy.
The -conglycinin product consisting of 88% pure -conglycinin, 5% soy protein, 2% minerals and 5% water was sterilized for food use and spray dried. The composition of the test candy is shown in Table 1 . The test candy contained 0.625 g of -congycinin product per piece. For the control experiment, placebo candy with the same taste as the test candy was produced by replacing -conglycinin with the milk protein casein (Table 1) .
Subjects
All of the test subjects were between 26 and 69 years of age.
Individuals undergoing treatment for hyperlipidemia, diabetes or liver dysfunction or with food or soybean allergies were excluded from the study. [Test 1] −According to the guidelines of the Japan Atherosclerosis Society 15) , the upper limit of the normal range for serum TG is 150 mg/dL (1.69 mmol/L), concentrations above this range being regarded as hyperlipidemic.
Subjects were screened twice before enrolment in the trial, to ensure that they were slightly hyperlipidemic with serum TG concentrations higher than 1.69 mmol/L. Seven hundred and forty-four volunteers were asked to complete a meal questionnaire including the TG value and to provide a blood sample 2 wk before the start of the study. Then, we designed a test period of a 2-wk pre-evaluation phase eating dinner of about 700 kcal per day, which was supplied by the Institute of General Health Development Co. Ltd. (Tokyo, Japan) to screen subjects. The high serum TG levels in a considerable number of subject candidates fell to below 1.69 mmol/L. The 138 subject candidates who still had high serum TG levels were registered as subjects and returned to regular daily meals.
[Test 2]−According to the guidelines of the Japan Society for the Study of Obesity 16) , a body mass index (BMI) between 25 and 30 is regarded as indicating obesity. Two hundred and fifteen volunteers were asked to complete a meal questionnaire about their dietary habits, 2 wk before the start of the study. One hundred and two subjects with slight hyperlipidemia with waist measurements of more than 85 cm (male) and 90 cm (female) showing BMI 25-30 were registered to participate in the study.
In compliance with the principles of the Helsinki Declaration and the study protocol, the purpose and methodology of the study, and the rights of the subjects were explained in advance and written consent was obtained from all volunteers.
Methods
Test Design
The study used a double-blind placebo-controlled design. Test 1 for Serum TG The subjects were assigned at random to one of two groups: the test group only consumed the test candy containing soybean -conglycinin (n 69) and the placebo group only consumed the casein-containing placebo candy (n 69). During the consumption period, blood samples were taken every 4 wk and a meal questionnaire was completed for the 3 d preceding each blood test. Subjects were instructed to consume four pieces of candy twice a day containing a total of 5 g soybean -conglycinin, i.e., before breakfast and dinner (0.625 g -conglycinin per piece four pieces twice a day 5 g). Those in the placebo group were given the casein candy in the same manner.
Test 2 for Visceral Fat
The numbers of subjects of the test and placebo groups separated randomly were 50 and 52, respectively. The consumption period was 20 wk.
During the consumption period, blood samples were taken at 8, 12, 16 and 20 wk. Meal questionnaires were completed throughout the test period. Subjects were instructed to consume four pieces of candy twice a day containing a total of 5 g soybean -conglycinin per subject, i.e., before breakfast and dinnerthose in the placebo group were given the casein candy in a same manner.
The subjects were prohibited from drinking alcohol for 3 d before giving blood samples; however, they were free to drink alcohol and smoke moderately at all other times during the consumption period.
Data Collection
Blood samples were collected from each participant periodically from the start of the consumption period. Blood samples were collected at 09:00 in the morning and the subjects were required to fast from 20:00 the previous night. The following hematological and serum biochemistry measurements were carried out by Scripps Reference Laboratory (Tokyo, Japan): white blood cell count, red blood cell count, hemoglobin, hematocrit, and platelet count; TG, free fatty acid, total cholesterol, high-density lipoprotein (HDL)-cholesterol, and low-density lipoprotein (LDL)-cholesterol for lipid metabolism; the enzymes glutamate-oxaloacetate transaminase (GOT), glutamate-pyruvate transaminase (GPT), gamma-glutamyl transpeptidase ( -GTP), alkaline phosphatase (ALP), and lactate dehydrogenase (LDH); total protein, albumin, blood urea nitrogen (BUN), uric acid, creatine, and total bilirubin for nitrogen metabolism; blood sugar and HbAlc for sugar metabolism; and the electrolytes Na, K, and Cl. For Test 1, apolipoproteins (Apo-A1, -2, -B, -C2, -3 and -E) and lipoprotein fractions were measured.
The concentrations of TG, total cholesterol and LDL-cholesterol were determined enzymatically. The HDL-cholesterol concentrations were measured by the synthetic polymer method. Apolipoprotein concentrations were measured by means of turbidimetric immunoassays. The concentrations of remnant-like particle (RLP)-cholesterol and RLP-TG of the lipoprotein fractions were measured by immunoseparation assays. The other lipoprotein fractions (Chylomicron, VLDL, LDL and HDL) were measured by the HPLC column method 17) by Skylight-biotech (Tokyo, Japan). At the time of blood collection, all subjects were also interviewed by a physician, in order to determine the occurrence of other subjective symptoms, and were assessed with a body composition meter, In body (Biospace Japan, Inc.), which calculated the body composition by bioelectrical impedance. For Test 2, the abdominal fat distribution was determined by five CT scans obtained around the umbilicus 13) , such as the area at the umbilicus, two areas 1 and 2 cm above the umbilicus, and two areas 1 and 2 cm below the umbilicus.
During the study period, the subjects recorded their diet by weight for 3 d before each blood sample was collected for Test 1, and throughout the test period for Test 2. The amounts of nutrients ingested by each subject were calculated by a nutritionist using a computer program (Excel Eiyo-kun ver. 3.0; Kenpakusha, Ltd., Tokyo, Japan). The subjects were also instructed at the start of the trial to record any symptoms associated with the study in a questionnaire and to add a description, including the severity or time of occurrence, for the physician.
Statistical Analysis
The unpaired t-test was used for multiple group comparisons of the initial clinical data and calorie intake, and the blood test results and body-composition data collected during the trial period. Additionally, analysis of covariance (ANCOVA) was performed for changes in data, with the initial values as covariates, using Bonferroni's correction for multiple comparisons in order to reveal significant differences between two groups. SPSS (SPSS 10.0J for Windows; SPSS Co., Tokyo, Japan) was used for all statistical analyses and a 5% significance level was applied in the twotailed tests.
Results
Test 1 for Serum TG Subjects
The background information on the 126 subjects in the both groups is summarized in Table 2 . Data for 12 subjects were excluded, since they did not comply with the test conditions as described in the Methods section.
The TG values in the -conglycinin and placebo groups were 2.65 0.09 and 2.54 0.09 mmol/L, respectively.
Calorie Intake
The diet data, which were obtained four times during the test period, are summarized in Table 3 .
There was no significant difference between the groups as to the total calorie intake or the consumption of individual nutrient groups (protein, lipid and carbohydrate) during the test period (data not shown). 
Serum TG
The mean serum TG concentration in the test group was initially 2.65 0.09 mmol/L, and was significantly reduced after 4, 8 and 12 wk of -conglycinin consumption, i.e., by 0.31 0.08, 0.26 0.09 and 0.36 0.09 mmol/L, respectively ( Table 2 and Fig. 1) . ANCOVA, using the initial serum TG concentration as a covariate, showed a significant difference after 4 and 12 wk (4 wk, F 5.038, P 0.027, and 12 wk, F 6.400, P 0.013), and a less significant reduction after 8 wk (F 3.335, P 0.070).
The mean serum free fatty acid concentration in the test group was initially 0.57 0.02 mEq/L, and was significantly reduced to 0.48 0.03 mEq/L after 12 wk of -conglycinin consumption ( Table 2 ). The concentration in the placebo group did not change during the test period.
Serum Apolipoprotein
The mean apolipoprotein B (ApoB) concentration in the test group decreased from a baseline value of 1.18 0.03 g/L by 0.024 0.016 and 0.017 0.019 g/L after 4 and 12 wk, respectively (Fig. 2) . By contrast, the placebo group showed an increase from a baseline concentration of 1.19 0.03 g/L, i.e., by 0.020 0.017 and 0.027 0.016 g/L, after 4 and 12 wk. In particular, after 4 wk, the ApoB concentration in both groups significantly increased. ANCOVA, using the initial ApoB concentration as a covariate, showed a significant change between the two groups after 4 wk (F 3.994, P 0.048), and significant tendency after 8 and 12 wk (8 wk, F 3.107, P 0.080, and 12 wk, F 3.464, P 0.065).
The apolipoprotein C concentration in the test group significantly decreased from the baseline value after 4 wk (data not shown), and apolipoprotein E in the same group significantly decreased after 4 and 12 wk ( Table 2) .
Lipoprotein Fraction
Chylomicron (CM)-TG, VLDL-TG, LDL-TG and HDL-TG were measured by HPLC 17) . The mean concentration of VLDL-TG in the test group significantly decreased from the baseline value after 12 wk ( Table 2 ). The placebo group showed a significant increase from the baseline. ANCOVA, using the initial concentration of VLDL-TG as a covariate, showed a significant change between the two groups (F 6.708, P 0.011). RLP-TG and cholesterol in the test group significantly decreased from the baseline value to 12 wk, respectively ( Table 2 ). The placebo group showed no significant change from the baseline. ANCOVA, using the initial RLP-TG and cholesterol as covariates, showed significant reductions during the -conglycinin consumption period (data not shown).
Other Blood Tests
Apart from the serum TG and apolipoprotein concentrations and the lipoprotein fraction, significant changes were not observed in blood hematology or biochemistry, such as the white blood cell count, red blood cell count, hemoglobin, hematocrit, platelet count, GOT, GTP, -GTP, ALP, LDH, total protein, albumin or blood sugar level (data not shown).
Test 2 for Visceral Fat Subjects
The background information on the subjects in both groups is summarized in Table 4a . Data for 7 subjects were excluded, since they did not comply with the test conditions as described in the Methods section. The visceral fat areas in the -conglycinin and shows a significant difference between initial and final data (p 0.05). shows a significant different tendency between initial and final data (p 0.1).
placebo groups were 107.5 6.6 and 102.3 6.1 cm 2 , respectively.
Calorie Intake
The diet data, which were obtained during the test period, are summarized in Table 5 . Significant differences were not observed between the groups as to the total calorie intake or the consumption of individual nutrient groups (protein, lipid and carbohydrate) during the test period (data not shown).
Abdominal Fat
For abdominal fat distribution, an average of 5 CT areas was measured around the umbilicus. The mean visceral fat area in the test group was initially 107.5 6.6 cm 2 , and was reduced after 12 wk ofconglycinin consumption, and significantly reduced after 12 and 20 wk consumption and 4 wk post-evaluation, i.e., by 5. (Table 4a and Fig. 3 ). By contrast, the placebo group showed a significant increase from the baseline of 102.3 6.1 cm 2 , i.e., by 4.2 1.6 cm 2 after 20 wk. ANCOVA, using the initial visceral area as a covariate, showed significant decreases caused by the intake of -conglycinin after 20 wk (F 8.164, P 0.005), and the 4 wk post-evaluation phase (F 4.719, P 0.032).
Among the subjects, 46 (24 in the test group including 12 men and 12 women, and 22 in the placebo group including 13 men and 9 women) had larger visceral fat areas than 100 cm 2 ( Table 4b ). The mean visceral fat area of those subjects in the test group was initially 136.9 7.5 cm 2 , and was reduced after 12 and 20 wk of -conglycinin consumption, i.e., by 7.1 4.0 cm 2 and 6.6 3.8 cm 2 , respectively (Table 4b and Fig. 4) .
They also showed a significant decrease, i.e., by 8.8 3.5 cm 2 after the 4 wk post-evaluation phase.
The placebo group of those subjects showed a significant increase from the baseline of 138.2 6.3 cm 2 , i.e., Test group (solid) and placebo group (open). Bars represent SEMs. ANCOVA, using the initial visceral fat area as a covariate, showed significant differences between the two groups ( p 0.05 and p 0.01).
by 6.0 2.6 cm 2 , after 20 wk (Table 4b and Fig. 4 ). The result of ANCOVA, using the initial visceral area as a covariate, showed a significant decrease caused by dietary -conglycinin after 20 wk (F 7.634, P 0.008) and the 4 wk post-evaluation phase (F 5.206, P 0.028).
Serum Lipids
The mean serum TG in the test group was reduced after 20 wk of -conglycinin consumption, but this reduction was not significant ( Table 4a ). The mean serum free fatty acid concentration in the test group was initially 0.48 0.03 mEq/L, and was significantly reduced to 0.40 0.03 mEq/L after 20 wk of -conglycinin consumption ( Table 4a ). The concentration in the placebo group did not change during the test period.
Discussion
Prior to Test 1 for serum TG, subjects with high serum TG levels were screened by their intake of restricted dietary calories for two weeks. The high serum TG levels in a considerable number of subject candidates were lowered to below 1.69 mmol/L. The candidate subjects, who still had high serum TG levels, participated in the test as subjects and returned to have regular daily meals. The subjects in Test 2 for visceral fat were screened by the similar methods as for Test 1. The increases in serum TG and visceral fat with the placebo may have been caused by such a change to daily meals. The three-month and five-month regulation for the test appeared to be hard for the subject volunteers, although most of them complied with the conditions and thus contributed to this study. Finally, it was shown that serum TG and visceral fat were lowered by dietary -conglycinin.
Soy has been cultivated and utilized as a food since ancient times. The US Food and Drug Administration (FDA) has approved for food labeling the health claim that the consumption of 25 g soy protein isolate per day, including 5 g -conglycinin 18) , reduces the risk of heart diseases 1) Hence, subjects who eat 5 g -conglycinin a day appear safe.
Daily consumption of 5 g -conglycinin per subject significantly lowered the serum TG concentration. Simultaneously, the apo B and VLDL-TG concentrations were significantly decreased.
Hence, -conglycinin consumption may specifically affect TG metabolism. In addition, the intake of 5 g -conglycinin per day decreased visceral fat. It seems difficult to determine the precise CT area of visceral fat. In order to overcome this problem, we developed a means of measuring CT areas more precisely. Five CT areas around the umbilicus were measured and averaged per subject. As a result, statistically significant data were obtained. Dietary -conglycinin was shown to decrease visceral fat. Visceral fat is now recognized as the key factor related to metabolic syndrome 19, 20) . During the test period, adiponectin significantly increased (Table 4a) , but there was no change between test and placebo groups. However, it cannot be excluded that the decrease in visceral fat may contribute to a decrease in portal free fatty acids. Indeed, serum free fatty acids in the test group significantly decreased ( Table 4a ).
The details of the mechanism underlying the decreased TG synthesis and accumulation caused byconglycinin remain unknown. However, it has been reported in mice and rats 11, 12) that feeding -conglycinin lowered fatty-acid synthetic activity, and increased the activities of -oxidation enzymes such as carnitine palmitoyl transferase and acyl-coA oxidase in the liver, and that fecal excretion of TG was increased.
This suggests that the concentration of the substrate (free fatty acids) for TG synthesis was decreased by -conglycinin consumption. Biochemical and molecular biological studies are currently under way.
The effectiveness of the daily intake of 5 gconglycinin, as described above, may support the FDA recommendation for the consumption of 25 g SPI a day, in which 5 g -conglycinin is included 18) . Therefore, -conglycinin might be an important food component for the prevention and/or amelioration of visceral fat syndrome, so-called metabolic syndrome.
